Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
Phase 2
332
about 19 years
18–72
1 site in MD
What this study is about
This trial is testing a new treatment that uses your own immune cells to fight cancer. The goal is to see if these TILs can shrink tumors and make the treatment safe.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Young TIL
- 2.Take Aldesleukin
- 3.Take Cyclophosphamide
- +2 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
aldesleukin, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), fludarabine, immunotherapy (PD-1 inhibitor immunotherapy (pembrolizumab)), pembrolizumab (Immune checkpoint inhibitor; blocks PD-1 to boost T-cell attack on cancer)
infusion
Primary: Response rate
Secondary: Frequency and severity of treatment-related adverse events
Endocrinology, Oncology